Avastin Update

Max Wallace, CEO of Accelerate Brain Cancer Cure, provides perspective on the latest Avastin study by Genentech.

Dear Friends,

I want to provide a brief update on Avastin, a treatment for patients with glioblastoma, the most common and aggressive form of brain cancer.

In early August, Genentech released information from their Avastin Phase III study in people with newly diagnosed glioblastoma. The study showed that Avastin, used in conjunction with standard radiation and temozolomide, met the study’s co-primary endpoint of significantly improving progression free survival (PFS) compared to the use of just radiation, temozolomide and placebo.

Hal Barron, Genentech’s Chief Medical Officer, said, “This study showed that people with glioblastoma, a particularly devastating and aggressive cancer without many treatment options, lived significantly longer without their disease worsening when Avastin was added to radiation and temozolomide chemotherapy.”

Data for overall survival (OS), the other co-primary endpoint, was not released and are not expected until 2013.

Click here for the Genentech press release.

From our perspective, it's promising that the study showed that patients "lived significantly longer without their disease worsening," but we need to see the actual data to understand more fully what this means. I will be talking with our scientific friends and advisors to gather more information.  We need to learn the extent to which Avastin improves overall survival.  We also want to understand how to optimize the use of Avastin, especially in conjunction with other treatments. 

During the next few months, as more data and feedback come in, I will keep you updated on this important issue to our community.

Sincerely,

Max Wallace

 

Share |
  • October 8, 2021 10:38 AM
    While the honorees expressed gratitude for the prize, their comments about their work were tinged with worry about the future of biomedical research after years of cuts in federal funding.
  • September 26, 2021 04:33 PM
    The researchers caution that many treatments have cured cancers in mice and then failed in humans. But they are encouraged by the new findings and want to work quickly to design a clinical trial for humans.
  • August 23, 2022 12:51 PM
    Researchers found that there was a “highly significant” increase in GBM patient survival in the year after Avastin was approved.
  • Sunday, October 27, 2021
  • Saturday, November 2, 2021 to Sunday, November 3, 2021
  • Join us in our fight for a cure!

    Twitter